Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of the drug ketamine for the treatment of depression in cancer
patients receiving palliative care. The purpose of this study is to see how useful the drug
is at decreasing the severity of depression these patients. Ketamine will be given through
the nose.